Related Experiment Videos
The origin of thrombolytic therapy
1Temple University School of Medicine, Philadelphia, Pennsylvania.
Journal of the American College of Cardiology
|October 1, 1989
Summary
Thrombolytic therapy, initiated 40 years ago, dissolves blood clots. Its use in acute myocardial infarction became standard after demonstrating clot dissolution in arteries and improved survival rates.
Area of Science:
- Cardiology
- Hematology
- Pharmacology
Background:
- Thrombolytic therapy originated from activating the plasminogen-plasmin system to dissolve clots.
- Early applications focused on chest clots, with intravascular thrombus dissolution requiring further advancements.
Discussion:
- The development of purified plasminogen activators proved more effective than plasmin for thrombolysis.
- Systemic administration of plasminogen activators was validated in animal and human studies for dissolving thrombi.
Key Insights:
- The first study of thrombolytic therapy for acute myocardial infarction was in 1958.
- Despite early promising results, widespread adoption required visual confirmation of thrombus lysis via angiography.
- Angiography confirmed prompt lysis of infarct-related artery thrombi, establishing the therapy's efficacy.
Outlook:
- Continued research into optimizing thrombolytic agents and delivery methods.
- Integration of advanced imaging techniques for precise treatment monitoring.
- Potential for broader applications in cardiovascular and other thrombotic conditions.